Potential Benefits. Opioids (morphine-like substances) are more effective in the treatment of acute pain than chronic pain. While opioids can at times abolish acute pain, the expected reduction of chronic pain is only about 20% at the beginning of the treatment period.
Potential Benefits. The benefit of sharing this information will be improved support to those affected by cuckooing; leading to reduced risk, increased safety, health and well being of adults
Potential Benefits. Potential benefits include improvement in the study participant’s lung function and other improvements that may be associated with improved lung function.
Potential Benefits. Potential benefits you may experience as a participant in the study include having improved lung function and other improvements that may be associated with improved lung function, such as improved quality of life. If it is determined that control group participants still meet study eligibility criteria and it seems clinically appropriate for them after their 1-year follow-up visit, the study sponsor will pay for these participants to undergo the EBV and bronchoscopy procedure. The primary risks associated with use of the Pulmonx EBV are similar to other bronchoscopic and surgical procedures used to treat emphysema. These are listed below. While this list is comprehensive, there may be other risks that are still unknown. The close monitoring that you will receive, as part of the study, should allow for detection of symptoms, should they be present. This, in turn, should allow for early intervention by your physician if that is necessary. Your physician will review all of the risks below with you so that you understand them. Previous clinical trial experience and experience from other countries around the world, where the EBV device is commercially available, has shown that in some people EBV treatment is associated with having a pneumothorax as a potential complication. A pneumothorax is a condition in which air leaks from the lung into the space between the lung and chest wall. This prevents the healthy lung from working well and can cause chest pain and shortness of breath. As many as 1 in 5 patients may experience a pneumothorax after the study procedure. Most of these tend to occur in the early period following the valve placement and usually resolve after staying in hospital for a few days. Most frequently, a treatment using a small tube to drain out the air is required. In rare cases, a pneumothorax may require a surgical intervention. In addition, there is a chance that it can be a serious and life- threatening complication. Potential Risks (Adverse Events) Acute bronchospasm (spasm of the airway; may result in wheezing or increased shortness of breath) Acute respiratory distress syndrome (sudden, severe injury to lungs) Airway blockage due to implant migration Airway perforation (hole in the airway wall) Airway stenosis (narrowing) Anxiety Aphonia (difficulty talking) Aspiration (inhalation of vomit) Bowel function impairment Bronchial (airway) trauma or ulceration Chest pain COPD exacerbation (acute worsening of COPD symptoms)
Potential Benefits. This cumulative data will be used as baseline information to partially assess the effectiveness of efforts to reduce the pollutant load to the wastewater collection system and measures designed to protect the watershed. Other anticipated benefits include a potential reduction of the concentration of toxic metals in the “Dyno Dirt” class AAA composted biosolids produced at the Pecan Creek Water Reclamation Plant. The potential reduction of metals concentrations in the compost will be assessed in relation to the accumulated baseline data.All of these benefits depend upon the City’s ability to allocate resources to maximize effort and minimize economic burden. The City of Xxxxxx firmly believes that with minor enhancement of our current organizational structure, a watershed protection program can be developed that will meet the intent of the Clean Water Act at a cost acceptable to rate payers.
Potential Benefits. The subject may or may not benefit from this study. Although CBBCT device has been approved by the FDA, the use of contrast agent in CBBCT scan has not received FDA approval. If unusual/unexpected findings are noted only in CE-CBBCT, the patient will be referred for further
Potential Benefits. With state-specific assumptions and inputs (such as background concentration, persistence factor, fleet mix, fuel mix, Inspection and Maintenance program, etc.), more project types (i.e., park and ride lots, skewed intersections, roundabouts, etc.) and/or more project conditions (i.e., road grade or number of lanes) could be shown to meet the CO NAAQS in each state. NCHRP 25-25 Task 78 modeled 4 project types: freeways, arterials, intersections and interchanges. This proposed research would build upon the work of Task 78 and develop and implement a state-specific CO project-level PA in 2-3 states. Information from this research could then be used to shorten and simplify the process for PA development and implementation for other state DOTs. This would benefit other state DOTs that wish to develop a CO project-level PA by enabling them to avoid or work around procedural, administrative or technical issues that were encountered and solved during this proposed research. Research is needed to identify and address issues with development and implementation of PAs to be used by state DOTs for determining which project types do not require a project-level CO analysis. It is expected that this research would require a number of project types and conditions to be modeled and analyzed with state-specific inputs and data. The research would encompass the entire process of PA development and implementation, from start through needed approvals and finally to implementation. Lessons learned from this research could then be used to inform the process for PA development and implementation for other state DOTs.
Potential Benefits. Entering into a PPA may have the following benefits: Reducing confrontation by working together to find solutions and encouraging positive input from consultees and third parties. Removing externally imposed timescales to give sufficient time to agree changes, improve quality, and meet policy objectives. Identifying and addressing the concerns of the local community early in the process. Increasing satisfaction by ensuring an opportunity for all parties to have their views heard and considered through open and honest dialogue. Increased certainty over the outcome of a proposal before an application is submitted. The PPA will set up a project team and will introduce a project management approach to the handling of development proposals. This will require a significant resource investment from all involved. In order to make this investment worthwhile, rights and responsibilities of all parties must be agreed to demonstrate a clear commitment to joint working. The Strategic Manager for Planning and Regeneration will secure corporate buy in to the project and lead on Councillor engagement. The Development Control Manager will be the Council’s lead officer to coordinate the project team, be the primary contact with the developer, ensure delivery of tasks to timetable, and regularly report back to the Strategic Manager. We will: • Arrange an inception meeting to agree a joint vision, discuss key issues, and draft an initial project plan. • Field the strongest available team to provide consistent professional advice • Agree a detailed project plan setting out key stages and milestones. • Arrange and administer further meetings of the project team • Advise on and facilitate internal and external consultation including with statutory consultees • Advise on community engagement in accordance with the Statement of Community Involvement • Ensure councillor engagement and facilitate the presentation of proposals where appropriate • Provide details of heads of terms to be included in any section 106 agreements. • Offer a pre-submission check to ensure a valid application is submitted Developer responsibilities: Good project management is required (from both parties) so that necessary tasks, negotiations or re-design can take place on time and on an agreed basis. The developer will: • Field an appropriate team with relevant professional advice • Agree a joint vision for the proposal • Agree a detailed project plan setting out key stages and milestones. • Engage in open a...
Potential Benefits. There is a potential benefit to participants of this study who are seeking temporary relief of axillary hyperhidrosis symptoms. Results of the study may contribute to developing an ultrasound-based, non-invasive axillary hyperhidrosis procedure.
Potential Benefits. The TFNT00 IOL is a single-piece, trifocal diffractive lens with a +3.25 D near ADD and +2.17 D intermediate ADD intended to provide optical performance and spectacle independence similar to the ACRYSOF IQ ReSTOR +3.0 D Multifocal IOL (Model SN6AD1) at near range (40 cm) and distance, with the additional benefit of intermediate vision at 60 cm. Xxxxxxx (2009) performed a randomized, parallel group, subject masked, multicenter 6 month follow-up study comparing ACRYSOF IQ ReSTOR +3.0 D Add Power IOL (Model SN6AD1) to ACRYSOF ReSTOR +4.0 D Add Power IOL (Model SN6AD3). Both lenses were implanted bilaterally. The effectiveness results at 6 months showed mean uncorrected distance visual acuity of 20/20 and binocular defocus curves demonstrated 20/20 visual acuity at 40 cm. The Patient Reported Outcomes with the SN6AD1 IOL were very favorable with reported spectacle independence rates in 76% of subjects in the ACRYSOF IQ ReSTOR +3.0 D Multifocal IOL (Model SN6AD1), high patient satisfaction, self-rated visual quality and substantial improvements in patient reported outcomes. The 839MP is a single-piece, trifocal diffractive IOL with a +3.33D near ADD and +1.66D intermediate ADD indicated to provide presbyopia correction in patients with or without cataract. In a case series study comprised of 30 patients who had bilateral implantation of the 839MP IOL after phacoemulsification for either cataract or refractive lens exchange surgery, the effectiveness results at 6 months showed mean uncorrected distance visual acuity of close to 20/20 for mean uncorrected monocular and binocular visual acuity (Law 2014). Similarly, binocular defocus demonstrated 20/30 visual acuity between distance and 33 cm. The majority of patients (77%) were satisfied with their distance, intermediate and near vision at the end of the follow up. Difficulties associated with photic phenomena (night vision, glare and halo perception) decreased significantly over time.
